Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Xencor Inc (NQ: XNCR ) 21.65 +0.38 (+1.79%) Streaming Delayed Price Updated: 4:00 PM EDT, Jul 26, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Xencor Inc < Previous 1 2 3 4 5 6 Next > Xencor: Q3 Earnings Insights November 08, 2021 Xencor (NASDAQ:XNCR) reported its Q3 earnings results on Monday, November 8, 2021 at 04:01 PM. Here's what investors need to know about the announcement. Earnings Xencor their... Via Benzinga Xencor Reports Third Quarter 2021 Financial Results and Announces Encouraging Preliminary Data from Ongoing Phase 1 Study of Potency-reduced IL15-Fc Cytokine, XmAb306 November 08, 2021 From Xencor, Inc. Via Business Wire Preview: Xencor's Earnings November 05, 2021 Xencor (NASDAQ:XNCR) is set to give its latest quarterly earnings report on Monday, 2021-11-08. Here's what investors need to know before the announcement. Analysts estimate that... Via Benzinga Xencor to Present Data from the Phase 1 Study of Plamotamab in B-Cell Malignancies at the American Society of Hematology Annual Meeting November 04, 2021 From Xencor, Inc. Via Business Wire Earnings Scheduled For November 8, 2021 November 08, 2021 Companies Reporting Before The Bell • Privia Health Group (NASDAQ:PRVA) is projected to report quarterly loss at $0.11 per share on revenue of $215.14 million. •... Via Benzinga Xencor Presents Clinical Data from the Phase 1 Study of Tidutamab in Neuroendocrine Tumors at NANETS’ Multidisciplinary NET Medical Virtual Symposium November 03, 2021 From Xencor, Inc. Via Business Wire Xencor to Present at Upcoming Investor Conferences November 02, 2021 From Xencor, Inc. Via Business Wire Xencor to Host Third Quarter 2021 Financial Results Webcast and Conference Call on November 8, 2021 November 01, 2021 From Xencor, Inc. Via Business Wire JNJ, Xencor Sign $1.3B Licensing Deal For B-Cell Malignancies-Targeted Bispecific Antibody October 04, 2021 Johnson & Johnson's (NYSE: JNJ) Janssen unit has inked a licensing deal worth $100 million in upfront cash and $25 million in equity for global... Via Benzinga Xencor Enters Global Collaboration and License Agreement With Janssen to Advance Plamotamab and XmAb CD28 Bispecific Antibody Combinations for the Treatment of Patients With B-Cell Malignancies October 04, 2021 From Xencor, Inc. Via Business Wire Xencor to Present Data from the Phase 1 Study of Vudalimab (XmAb®717) and Four Research Programs at the SITC Annual Meeting October 01, 2021 From Xencor, Inc. Via Business Wire Xencor to Present at the 2021 Cantor Virtual Global Healthcare Conference September 20, 2021 From Xencor, Inc. Via Business Wire The Daily Biotech Pulse: MorphoSys-Incyte Snag European Nod, Immutep Granted Chinese Patent, Bolt Biotherapeutics Strike Oncology Collaboration August 27, 2021 Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 26) Agenus Inc. (NASDAQ: AGEN)... Via Benzinga Topics Intellectual Property Exposures Intellectual Property Return on Capital Employed Insights for Xencor August 20, 2021 After pulling data from Benzinga Pro it seems like during Q2, Xencor (NASDAQ:XNCR) earned $9.09 million, a 157.98% increase from the preceding quarter. Xencor also posted a total... Via Benzinga Incyte Out Licenses Lymphoma Drug To InnoCare In Greater China August 17, 2021 Incyte Corporation (NASDAQ: INCY) and InnoCare have entered into a collaboration and license agreement to develop and commercial tafasitamab in Greater... Via Benzinga Stocks That Hit 52-Week Lows On Friday August 20, 2021 On Friday morning, 155 companies achieved new lows for the year. Interesting Points: Marqeta (NASDAQ:MQ) was the largest firm on a market cap basis to set a new 52-... Via Benzinga Xencor, inc (XNCR) Q2 2021 Earnings Call Transcript August 04, 2021 XNCR earnings call for the period ending June 30, 2021. Via The Motley Fool Topics Earnings Exposures Financial Xencor Reports Second Quarter 2021 Financial Results August 04, 2021 From Xencor, Inc. Via Business Wire Xencor to Present at Upcoming Investor Conferences August 02, 2021 From Xencor, Inc. Via Business Wire Xencor to Host Second Quarter 2021 Financial Results Webcast and Conference Call on August 4, 2021 July 28, 2021 From Xencor, Inc. Via Business Wire Xencor to Present at the Jefferies Virtual Healthcare Conference May 27, 2021 From Xencor, Inc. Via Business Wire The Daily Biotech Pulse: Pfizer's Positive Readout, NRx Strikes R&D Collaboration With Mannkind, Cerus & Invitae Jump On Earnings August 04, 2021 Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 3) Absci, CORP (NASDAQ: ABSI) (... Via Benzinga Earnings Scheduled For August 4, 2021 August 04, 2021 Companies Reporting Before The Bell • UroGen Pharma (NASDAQ:URGN) is projected to report earnings for its second quarter. • Vericel (NASDAQ:VCEL) is expected to... Via Benzinga The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs August 01, 2021 Biotech stocks showed a lack of direction in the week ending July 30 amid earnings releases from big pharma companies. Most pharma majors reported strong quarterly results.... Via Benzinga Exposures Product Safety Sotrovimab (VIR-7831), an Investigational Antibody Utilizing Xencor's Xtend™ Technology, Receives U.S. FDA Emergency Use Authorization for the Treatment of COVID-19 May 26, 2021 From Xencor, Inc. Via Business Wire Bristol Myers Licenses Xencor's Technology Platform to Extend Half-Life of COVID-19 Antibodies May 25, 2021 Xencor Inc (NASDAQ: XNCR has entered into a technology license agreement with Bristol-Myers Squibb Co (NYSE: BMY), under which BMY will have non-exclusive access... Via Benzinga Exposures COVID-19 Xencor and Bristol Myers Squibb Enter License Agreement for Use of Xtend™ XmAb® Technology in SARS-CoV-2 Neutralizing Monoclonal Antibody Combination for the Treatment of COVID-19 May 25, 2021 From Xencor, Inc. Via Business Wire Xencor to Present at the 2021 RBC Capital Markets Global Healthcare Virtual Conference May 12, 2021 From Xencor, Inc. Via Business Wire Xencor Inc (XNCR) Q1 2021 Earnings Call Transcript May 06, 2021 XNCR earnings call for the period ending March 31, 2021. Via The Motley Fool Topics Earnings Exposures Financial Xencor Reports First Quarter 2021 Financial Results May 05, 2021 From Xencor, Inc. Via Business Wire < Previous 1 2 3 4 5 6 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.